Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedLTS:0JAV +0.77%67 Debt-to-Equity is 0.77 as of Jun. 2026, which is 24% below its 10-year median of 1.01. GuruFocus rates LTS:0JAV with a GF Score™ of 67/100 and a GF Value™ of $196.53 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, Insmed ranks worse than 83.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Insmed's Debt-to-Equity or its related term are showing as below:
LTS:0JAV'
s Debt-to-Equity Range Over the Past 10 Years
Min: -27.7 Med: 1.01 Max: 31.36
Current: 0.77
During the past 13 years, the highest Debt-to-Equity Ratio of Insmed was 31.36. The lowest was -27.70. And the median was 1.01.
LTS:0JAV's Debt-to-Equity is ranked worse than 83.83% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs LTS:0JAV: 0.77
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Insmed Debt-to-Equity Related Terms
Insmed Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Insmed's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JAV vs INCY, BNTX, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Insmed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Insmed's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (LTS:0JAV) has a Debt-to-Equity of 0.77 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Insmed and its competitors. This is 24% below median its historical median of 1.01. According to the industry distribution chart, Insmed ranks #809 out of 965 companies in the Biotechnology industry, placing it in the top 83.8%.
Is Insmed's Debt-to-Equity too high?
Insmed's current Debt-to-Equity of 0.77 is 24% below median its 10-year median of 1.01. The Biotechnology industry median Debt-to-Equity is 0.15. Insmed's value of 0.77 is 413.3% above this industry median. Based on the distribution chart, Insmed ranks #809 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Insmed has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Debt-to-Equity compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #809 out of 965 companies for Debt-to-Equity. This places Insmed in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Insmed's value of 0.77 is 413.3% above this benchmark. While the company's 10-year median is 1.01 vs. the industry median of 0.15, Insmed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insmed's current Debt-to-Equity of 0.77 is 413.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Insmed and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current Debt-to-Equity is 0.77, which is 24% below median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (LTS:0JAV) is currently considered Possible Value Trap. The stock's GF Value™ is $196.53, compared to a current price of $128.22 — trading 34.8% below its estimated fair value. The current Debt-to-Equity is 0.77, which is 24% below median its 10-year median of 1.01 and 413.3% above the Biotechnology industry median of 0.15. Insmed's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Insmed (LTS:0JAV), the current Debt-to-Equity is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (LTS:0JAV) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of $128.22 is trading 34.8% below its estimated GF Value™ of $196.53.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for LTS:0JAV:
Debt-to-Equity: 0.77 (24% below median its 10-year median of 1.01)
GF Value™: $196.53 vs. price of $128.22 (34.8% below fair value)
Industry Position: 413.3% above the Biotechnology median (#809 of 965)
No single metric tells the full story. See the LTS:0JAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
67GF Score
Get the complete analysis for LTS:0JAV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JAV has been successfully added to your 
